PMID- 31445985
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 1934-8150 (Electronic)
IS  - 1551-7411 (Linking)
VI  - 16
IP  - 6
DP  - 2020 Jun
TI  - Demographic and health-related predictors of proton pump inhibitor (PPI) use and 
      association with chronic kidney disease (CKD) stage in NHANES population.
PG  - 776-782
LID - S1551-7411(19)30087-7 [pii]
LID - 10.1016/j.sapharm.2019.08.032 [doi]
AB  - BACKGROUND: Reports of adverse outcomes with use of Proton Pump Inhibitors (PPIs) 
      and recent associations between PPI use and Chronic Kidney Disease (CKD) suggest 
      the need to examine PPI use in the general population. OBJECTIVES: The purpose of 
      this study was to examine PPI use in the general U.S. population with a focus on 
      CKD stages. METHODS: This was a retrospective database study of the National 
      Health and Nutrition Examination Survey (NHANES) for years 2009-2013. Inclusion 
      criteria were age >/= 18 years and having a serum creatinine value. The Andersen 
      Behavioral Model of Health Services Utilization and previous research were used 
      to identify the independent variables. Dependent variable was self-reported 
      prescription medication use. Multinomial logistic regression models were used to 
      examine factors associated with PPI use. RESULTS: Overall, the weighted 
      prevalence of PPI use was 8.7%. Only 4.5% of the sample had stage 3 or 4 CKD. PPI 
      use was highest among whites (10.5%) compared to minorities. PPI users were 
      significantly older (mean = 59.8years), with a majority (80%) being 50 years and 
      over. In multivariate analyses, PPI use was associated with having two or more 
      comorbidities (OR = 3.8, CI: 2.85-5.13), and having fair/poor health (OR 4.6 
      (3.5-5.9). Stage 3 and 4 CKD patients had higher odds of using PPIs (stage 3 
      OR = 3.8 CI: 2.5-5.8, stage 4 OR = 6.5 CI: 1.6-25.8) compared to stage 1 
      patients. CONCLUSION: /Relevance: This is the first study to examine both 
      predictors and racial disparities in PPI use in the general US population. While 
      PPI use was low, there were racial disparities in PPI use. Multiple comorbid 
      conditions, lower quality of life, and stage 3/4 CKD were associated with PPI 
      use. Awareness of these predictors will enable clinicians to target key patient 
      groups for tailored education and closer monitoring of PPI use.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Devraj, Radhika
AU  - Devraj R
AD  - Department of Pharmaceutical Sciences, Southern Illinois University Edwardsville, 
      USA. Electronic address: rdevraj@siue.edu.
FAU - Deshpande, Maithili
AU  - Deshpande M
AD  - Department of Pharmacy Practice, Southern Illinois University Edwardsville, USA.
LA  - eng
PT  - Journal Article
DEP - 20190819
PL  - United States
TA  - Res Social Adm Pharm
JT  - Research in social & administrative pharmacy : RSAP
JID - 101231974
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adolescent
MH  - Humans
MH  - Nutrition Surveys
MH  - Prevalence
MH  - *Proton Pump Inhibitors/adverse effects
MH  - Quality of Life
MH  - *Renal Insufficiency, Chronic/epidemiology
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Chronic kidney disease (CKD)
OT  - Medication use
OT  - NHANES
OT  - Proton pump inhibitor (PPI)
OT  - Racial disparities
OT  - Retrospective database
EDAT- 2019/08/26 06:00
MHDA- 2021/07/29 06:00
CRDT- 2019/08/26 06:00
PHST- 2019/02/05 00:00 [received]
PHST- 2019/08/09 00:00 [revised]
PHST- 2019/08/17 00:00 [accepted]
PHST- 2019/08/26 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2019/08/26 06:00 [entrez]
AID - S1551-7411(19)30087-7 [pii]
AID - 10.1016/j.sapharm.2019.08.032 [doi]
PST - ppublish
SO  - Res Social Adm Pharm. 2020 Jun;16(6):776-782. doi: 10.1016/j.sapharm.2019.08.032. 
      Epub 2019 Aug 19.